The investment significantly expands Ashland's pharmaceutical footprint in the region and capabilities to meet increasing market demand for coated tablets in Latin America and Brazil. Between 2019 and 2023 the consumption of coated tablets in Latin America had an average growth of 4.3 percent per year, while Brazil has reached growth of 5.7 percent per year+.
The investment also includes the modernization of equipment for microbial protection in personal care applications at the Research and Development (R&D) laboratory of the company's Technical Center in São Paulo and follows the company's previous investments to expand their bioresorbable polymers facility in Mullingar, Ireland and biofunctionals R&D lab in Shanghai, China.